Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Novartis trial marks ResearchKit first in MS

ElevateMS study will allow participants to contribute from smartphones

Novartis MS smartphone Apple iPhone ResearchKit study

Novartis has launched the first large-scale research study in multiple sclerosis using Apple’s ResearchKit software.

Participants will be able to contribute directly from their smartphones, via sensors that will collect movement and symptom data, removing the need for clinic visits.

The US mobile-enabled study uses a free-to-download iPhone app that was built on Apple’s ResearchKit platform, software that’s already in use at companies such as GlaxoSmithKline and Celgene.

Novartis’ Evaluation of Evidence from Smart Phone Sensors and Patient-Reported Outcomes in Participants with Multiple Sclerosis, or elevateMS, study aims to improve understanding of patients’ daily challenges.

The Swiss pharma firm and its tech partner Sage Biosystems also hope real-time data collection will enable them to uncover new potential measurements of treatment effectiveness.

Stanley Cohan, medical director at Providence Multiple Sclerosis Center in Portland, Oregon, is a scientific advisor to the study.

He said: “As physicians, we always want to know how our patients with MS are doing on the treatments we prescribe.

“With the elevateMS app, study participants can frequently document their symptoms in a personal health story. In turn, this data may provide researchers with new ways to look at disease progression and treatment effectiveness.”

The elevateMS mobile app can be downloaded from the Apple App Store and offers users a range of activities, including brainteasers and questionnaires about their health, while taking measures from the iPhone’s built-in sensors.

The study is only open to adults in the US that own an iPhone (4s or newer model), but participants with and without MS can sign up to help researchers better understand what it’s like to live with the condition.

22nd August 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite Digital

Graphite is a digital agency which partners with globally respected healthcare organisations to create powerful digital experiences. We help our...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics